Zymeworks PE Ratio 2016-2022 | ZYME

Current and historical p/e ratio for Zymeworks (ZYME) from 2016 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Zymeworks PE ratio as of December 01, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Zymeworks PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-12-01 7.73 0.00
2022-06-30 5.30 $-4.36 0.00
2022-03-31 6.55 $-4.70 0.00
2021-12-31 16.39 $-4.38 0.00
2021-09-30 29.04 $-4.17 0.00
2021-06-30 34.69 $-4.35 0.00
2021-03-31 31.58 $-3.81 0.00
2020-12-31 47.26 $-3.58 0.00
2020-09-30 46.58 $-4.50 0.00
2020-06-30 36.07 $-3.77 0.00
2020-03-31 35.47 $-3.89 0.00
2019-12-31 45.46 $-3.68 0.00
2019-09-30 24.80 $-1.73 0.00
2019-06-30 22.00 $-1.62 0.00
2019-03-31 16.18 $-0.95 0.00
2018-12-31 14.68 $-1.35 0.00
2018-09-30 15.70 $-0.36 0.00
2018-06-30 14.78 $-0.40 0.00
2018-03-31 12.02 $-0.83 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.486B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.688B 10.41
GSK (GSK) United Kingdom $70.345B 8.82
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.600B 0.00
Arcus Biosciences (RCUS) United States $2.547B 38.23
Biohaven (BHVN) United States $1.078B 0.00
Emergent Biosolutions (EBS) United States $0.614B 4.82
ADC Therapeutics SA (ADCT) Switzerland $0.281B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.074B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00